Target and Its Patented Drug(s)
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T07217 | Target Info | |||
Target Name | Fatty acid-binding protein 4 (FABP4) | ||||
Synonyms | Fatty acid-binding protein, adipocyte; Adipocyte-type fatty acid-binding protein; Adipocyte lipid-binding protein; Adipocyte fatty-acid-binding protein; Adipocyte fatty binding protein; ALBP; AFABP; A-FABP | ||||
Target Type | Patented-recorded Target | ||||
Gene Name | FABP4 | ||||
Biochemical Class | Fatty acid binding protein | ||||
UniProt ID |
Patent(s) and the Corresponding Patented Drug(s) | Top | ||||
---|---|---|---|---|---|
World Intellectual Property Organization (WIPO) | |||||
Patent ID | WO2014146995 | ||||
Title | Urea Derivatives and Their Use As Fatty-Acid Binding Protein (Fabp) Inhibitors. | ||||
Abstract | The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, W, A and B are as described herein, compositions including the compounds and methods of using the compounds. | ||||
Applicant(s) | F. Hoffmann-La Roche Ag | ||||
Representative Drug(s) | D01TJW | Drug Info | IC50 = 50 nM | Click to Show More | [1] |
United States Patent and Trademark Office (USPTO) | |||||
Patent ID | US8889683 | ||||
Title | Substituted Quinoxalines As Inhibitors of Fatty Acid Binding Protein. | ||||
Representative Drug(s) | D0Q9LM | Drug Info | Kd = 0.1 nM | Click to Show More | [1] |
Patent ID | US2014029723 | ||||
Title | Compositions, formulations and Methods for Treating Ocular Diseases. | ||||
Representative Drug(s) | D0R9RK | Drug Info | IC50 = 10 nM | Click to Show More | [1] |
Patent ID | US20130116234 | ||||
Title | Aryl-Quinoline Derivatives. | ||||
Representative Drug(s) | D06JEA | Drug Info | IC50 = 13.2 nM | Click to Show More | [1] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.